NEW YORK, NY / ACCESSWIRE / December 22, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Adamas Pharmaceuticals, Inc. (NASDAQGM: ADMS)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?prid=5010&wire=1
Lead Plaintiff Deadline: February 10, 2020
Class Period: August 8, 2017 to September 30, 2019
Allegations against ADMS include that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.
Sealed Air Corporation (NYSE: SEE)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sealed-air-corporation-loss-submission-form?prid=5010&wire=1
Lead Plaintiff Deadline: December 31, 2019
Class Period: November 5, 2014 to August 6, 2018
Allegations against SEE include that: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating the Company's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.
Twitter, Inc. (NYSE: TWTR)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/twitter-inc-loss-submission-form?prid=5010&wire=1
Lead Plaintiff Deadline: December 30, 2019
Class Period: August 6, 2019 to October 23, 2019
The filed complaint alleges that defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Twitter's common share price and operated as a fraud or deceit on purchasers of Twitter common stock by misrepresenting the Company's operating condition and future business prospects. The scheme was perpetrated by making positive statements about Twitter's business while defendants knew, or disregarded with deliberate recklessness, certain adverse facts. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Twitter's common stock fell precipitously.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong